Aktis Oncology (NASDAQ:AKTS) Director Ken Herrmann Sells 4,856 Shares

Aktis Oncology (NASDAQ:AKTS) Director Ken Herrmann sold 4,856 shares of the stock in a transaction on Monday, July 20th. The stock was sold at an average price of $24.56, for a total value of $119,263.36. Following the completion of the sale, the director owned 3,506 shares in the company, valued at $86,107.36. This trade represents a 58.07% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Aktis Oncology Stock Performance

Aktis Oncology stock traded down $0.78 during midday trading on Tuesday, hitting $23.43. 90,728 shares of the company’s stock were exchanged, compared to its average volume of 346,048. The firm has a market capitalization of $1.25 billion and a P/E ratio of -61.66. The stock’s 50-day moving average price is $23.98. Aktis Oncology has a 52-week low of $14.72 and a 52-week high of $34.19.

Aktis Oncology (NASDAQ:AKTS) last released its quarterly earnings results on Monday, May 11th. The technology company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.01). The business had revenue of $3.23 million during the quarter, compared to analysts’ expectations of $2.23 million. As a group, research analysts expect that Aktis Oncology will post -1.64 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on AKTS. Wall Street Zen downgraded Aktis Oncology from a “hold” rating to a “sell” rating in a research report on Saturday. Raymond James Financial started coverage on shares of Aktis Oncology in a research report on Monday, June 15th. They issued a “strong-buy” rating and a $40.00 price objective on the stock. William Blair began coverage on Aktis Oncology in a research note on Wednesday, April 29th. They issued an “outperform” rating on the stock. JPMorgan Chase & Co. upped their price target on Aktis Oncology from $30.00 to $33.00 and gave the company an “overweight” rating in a research report on Tuesday, July 14th. Finally, HC Wainwright lifted their price objective on Aktis Oncology from $33.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, June 2nd. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $34.60.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.